The NZD/JPY pair declined mildly to 91.40 on Thursday's session and continued trading within the range of 92.00-91.00.

Arcturus Therapeutics (ARCT) is continuing to evaluate the use of LUNAR-CF [ARCT-032] for the treatment of patients with Cystic Fibrosis [CF]. Read our latest report on the stock here.

An In-Depth Guide to Leveraging MetaTrader 5 and RSI Indicators for Advanced Trading Strategies in California's Evolving ...

After the Nifty closed below the critical 23,800 support level on Thursday Choice Brokings executive director Sumeet Bagadia ...

Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...

The U.S. stock market has hit 50 new highs so far this year. Investors are now anticipating tax cuts and further fiscal ...

In an era where the consequences of climate change are becoming alarmingly evident, the role of responsible investing has ...